Premium
Muscle Study Group Annual Scientific Meeting: Neuromuscular Therapeutics: Bench to Bedside and Beyond, Snowbird Ski & Summer Resort, Snowbird, UT, September 23–25, 2017
Author(s) -
van Schaik, I. N.,
Bril, V.,
van Geloven, N.,
Hartung, H. P.,
Lewis, R. A.,
Sobue, G.,
Lawo, J. P.,
Mielke, O.,
Durn, B. L.,
Cornblath, D. R.,
Merkies, I. S. J.,
Dimachkie, M. M.
Publication year - 2017
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.25768
Subject(s) - medicine , physical therapy , medical education , aeronautics , engineering
Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) often require long-term intravenous immunoglobulin (IVIG) maintenance therapy. Subcutaneous immunoglobulin (SCIG) offers an alternative administration option with anticipated improvements in patient quality of life, convenience, and flexibility. To evaluate IgPro20 (SCIG) as a maintenance treatment in CIDP. A randomized, double-blind trial in CIDP patients (n=172) investigated 0.2 and 0.4 g/kg weekly doses of IgPro20 versus placebo. The primary outcome was percentage of patients with CIDP relapse/withdrawal during 24-weeks of treatment determined by Inflammatory Neuropathy Cause and Treatment score. Secondary endpoints included grip strength and patient satisfaction. Both IgPro20 doses significantly reduced rate of CIDP relapse/withdrawal versus placebo. Grip strength remained stable with Hizentra®, but deteriorated with placebo. Most subjects preferred SCIG over IVIG. Local reactions, reported in 33% of IgPro20-treated patients, were mild or moderate in intensity. IgPro20 is efficacious and well-tolerated as maintenance treatment in CIDP. This article is protected by copyright. All rights reserve